611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Staying Social Can Boost Healthy 'Gray Matter' in Aging BrainsDNA Analysis Might Reveal Melanoma RiskGenetics Might Explain Some Cases of Cerebral PalsyDiabetes Drug Metformin May Protect the Aging BrainNew Research Links Another Gene to Alzheimer's RiskYour Sex Affects Your Genes for Body Fat, Cancer, Birth WeightExperimental Drug Shows Promise Against ALSCould Gene Therapy Stem the Damage of Parkinson's?Genetic Research May Help Identify Causes of StillbirthBlood Test Heralds New Era in Alzheimer's DiagnosisMore Clues to the Genes Behind Hearing LossScientists Move Closer to Mapping Entire Human GenomeBlood Test May Reveal Concussion Severity With Accuracy of Spinal TapDeep Brain Stimulation May Slow Parkinson's, Study FindsStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsYour Genes May Affect How You'll Heal If WoundedEven Without Concussion, Athletes' Brains Can Change After Head Jolts: StudyHealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead">HealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead
HealthDay In-Depth
The AI Revolution: Giving Docs a Diagnostic Assist">HealthDay In-Depth
The AI Revolution: Giving Docs a Diagnostic Assist
Blood Test Might Predict Worsening MSKeto Diet Might Change Your Gut in More Ways Than OneParkinson's Patient Improving After First-Ever Stem Cell TherapyKey Areas of the Brain Triggered in Recent Heart Attack SurvivorsFirst Good Evidence That Brain Hits 'Replay' While You SleepSome NFL Players May Be Misdiagnosed With Brain Disease: StudyGreenhouse Gases Bad for Your BrainTransplanted Skin Stem Cells Help Blind Mice See LightBrain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: Study'It's Like You Have a Hand Again': New Prosthetic Gets Closer to the Real ThingLosing a Spouse Could Speed Brain's DeclinePaddles Against Parkinson's: Ping Pong Might Ease SymptomsIn a First, Doctors Use Robotics to Treat Brain AneurysmSkiers Study Suggests Fitness May Stave Off Parkinson'sCRISPR Gene Editing Creates 'Designer' Immune Cells That Fight CancerGene Variant Ups Dementia Risk in Parkinson's Patients: StudyGene Variation May Protect Against Alzheimer's: StudyYoung-Onset Parkinson's May Start in the Womb, New Research SuggestsNew Gene Study Unravels Cancer's SecretsDoes Size Matter? Volume of Brain Area Not Always Tied to Memory, ThinkingGene Test Might Spot Soccer Players at High Risk for Brain TroubleSevere Deprivation in Childhood Has Lasting Impact on Brain SizeIn the Future, Could Exercise's Benefits Come in a Pill?Could Brain Scans Spot Children's Mood, Attention Problems Early?Brain Damage Changes Over Time in Boxers, MMA FightersSpecial 'Invisible' Dye Could Serve as Skin's Vaccination RecordCancer Drug Shows Promise for Parkinson's Patients'Smart' Contact Lenses Might Also Monitor Eye HealthCould Obesity Alter a Child's Brain Structure?Playing Sports Might Sharpen Your HearingAntarctic Study Shows Isolation, Monotony May Change the Human Brain
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Brain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: Study

HealthDay News
by -- Robert Preidt
Updated: Apr 13th 2020

new article illustration

MONDAY, April 13, 2020 (HealthDay News) -- Even before symptoms develop, the brains of people with early Alzheimer's disease have high levels of amyloid protein plaques, a new study reveals.

Those levels in older adults with no dementia symptoms are associated with a family history of disease, lower scores on thinking/memory tests, and declines in daily mental function.

The first findings from the so-called A4 study funded by the U.S. National Institute on Aging (NIA) were published recently in the journal JAMA Neurology. A4 stands for Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease.

The study -- due for completion in late 2022 -- is an ongoing trial that was launched in 2014. It's investigating whether the drug solanezumab can slow mental decline associated with elevated amyloids if people start taking it before Alzheimer's symptoms emerge.

Amyloid, a hallmark of Alzheimer's, has been the target of experimental treatments in clinical trials involving people who already have symptoms of the disease.

"A major issue for amyloid-targeting Alzheimer's disease clinical trials, and one that is being addressed with the A4 study, is that previous trials may have been intervening too late in the disease process to be effective," said NIA director Dr. Richard Hodes.

"A4 is pioneering in the field because it targets amyloid accumulation in older adults at risk for developing dementia before the onset of symptoms," he noted in a NIA news release.

The researchers used amyloid positron emission tomography (PET) imaging to screen nearly 4,500 older adults for the study. The investigators identified and enrolled more than 1,300 with high amyloid levels in the brain, but no Alzheimer's symptoms.

The study was the first to use PET to identify people with high levels of amyloid but no signs of mental ("cognitive") decline, according to Laurie Ryan, chief of the NIA's Dementias of Aging branch.

"Before the availability of amyloid PET, other amyloid-targeting clinical trials may have been testing therapies in some people who didn't have amyloid," she said in the news release.

Lead author Dr. Reisa Sperling, of the neurology department at Brigham and Women's Hospital in Boston, said screening data for all those who had PET scans is available to other researchers. It may help improve screening and enrollment in other trials designed to prevent Alzheimer's in people without symptoms, she said.

According to Ryan, "A4 demonstrates that prevention trials can enroll high-risk individuals -- people with biomarkers for Alzheimer's who are cognitively normal. Ultimately, precision medicine approaches will be essential."

She predicted that Alzheimer's disease will never have a "one-size-fits-all" treatment. "We're likely to need different treatments, even combinations of therapies, for different individuals based on their risk factors," Ryan explained.

More information

The Alzheimer's Association has more on Alzheimer's disease.